


Solid-Phase Synthesis of a Monofunctional *trans*- a_2Pt^{II} Complex Tethered to a Single-Stranded Oligonucleotide**

Kathrin S. Schmidt, Dmitri V. Filippov,
Nico J. Meeuwenoord, Gijs A. van der Marel,
Jacques H. van Boom,* Bernhard Lippert, and
Jan Reedijk*

Single-stranded oligonucleotides bind with high selectivity to complementary sequences within DNA or RNA. This important feature allows regulation of gene expression at the stage of transcription (antigene strategy) or translation (antisense strategy).^[1] Effectuation of this idea in combating cancer and AIDS seems promising.^[2, 3] So far the general applicability of this concept is, however, hampered by the observation that the adducts of oligonucleotides with DNA or RNA do not fully survive the replication and transcription machinery.^[4, 5]

Model studies indicated that cross-linking of an oligonucleotide and its target by a *trans*- a_2Pt^{II} species ($a = \text{NH}_3$ or amine) is a potential solution to this problem.^[6] The implementation of this concept in the antigene and antisense strategy is limited due to the lack of an efficient synthesis of selectively platinated oligonucleotides. For instance, the reaction of an oligonucleotide with a Pt^{II} species does not proceed regioselectively, resulting in tedious and time-consuming purification of the end product. On the other hand, incorporation of preplatinated nucleotide building blocks in an oligonucleotide by solid-phase DNA synthesis appears to be more rewarding in achieving specific and sequence-independent platination.^[7, 8] Unfortunately, the preparation of *trans*- a_2Pt^{II} -modified oligonucleotides by this method is accompanied by the formation of an inactivated species, which excludes cross-linking with target molecules.^[8]

Here we report a novel solid-phase approach to an oligonucleotide-tethered monofunctional *trans*- Pt^{II} complex with cross-linking ability. The newly synthesized *trans*- Pt^{II} building unit **2** (Scheme 1), in which the Pt^{II} center is inter alia coordinated to 1-amino-hexan-6-ol (AHOL) and 1-*N*-cyclohexylmethylthymine (CHMT), was designed to execute essential chemical manipulations en route to the target compound (i.e., **9** in Scheme 2). Thus, the primary hydroxyl group of the AHOL ligand served to tether **2** through a phosphate bond to the 5'-terminus of immobilized DNA.



Scheme 1. a) *o*-NPT; b) $\text{I}_2/\text{collidine}$; c) 25% aq. NH_3 ; d) 80% aq. AcOH ; e) DCl (pD 2.2). DMTr = 4,4'-dimethoxytrityl.

Moreover, the presence of the cyclohexylmethyl moiety, instead of a methyl group,^[9] would enhance the solubility of **2** in organic solvents. Apart from this, it was essential to establish whether the Pt^{II} center in **2** would be compatible with the solid-phase synthesis of DNA. The latter prerequisite is of primary importance in effecting exchange of the CHMT ligand by a chloro ligand,^[9] thus giving access to a monofunctionally platinated, single-stranded oligonucleotide in the final stage of the synthesis.


The viability of our strategy was explored first by executing the following solution-phase experiment (Scheme 1): Compound **2** was condensed with 5-(*ortho*-nitrophenyl)-1-*H*-tetrazole (*o*-NPT) to give, after oxidation of the intermediate phosphite, the corresponding phosphotriester derivative. Removal of the β -cyanoethyl group by treatment with concentrated aqueous ammonia resulted, after purification by reverse-phase HPLC, in the isolation of the homogeneous compound **3a**. The identity of **3a** was firmly established by ^1H , ^{31}P , and ^{195}Pt NMR spectroscopy as well as LC-MS. It was also verified that **3a** survived the forced ammonolysis conditions (6 h at 50°C) usually applied for the removal of *N*-acyl protecting groups of deoxynucleoside building units, clearly indicating that **2** is fully compatible with the DNA synthesis protocol. Transformation of **3a** into the required chloro derivative **3c** could be realized by the following two-step

[*] Prof. J. H. van Boom, Prof. J. Reedijk, Dipl.-Chem. K. S. Schmidt, Dr. D. V. Filippov, N. J. Meeuwenoord, Dr. G. A. van der Marel
Leiden Institute of Chemistry
Gorlaeus Laboratories, Leiden University
2300 RA Leiden (The Netherlands)
Fax: (+31) 71-527-4451 (J. Reedijk)
(+31) 71-527-4307 (J. H. van Boom)
E-mail: j.boom@chem.leidenuniv.nl
reedijk@chem.leidenuniv.nl

Prof. B. Lippert
Fachbereich Chemie, Universität Dortmund
Otto-Hahn-Strasse 6, 44227 Dortmund (Germany)

[**] $a = \text{NH}_3$ or amine. This work was supported by the DAAD (Doktorandenstipendium im Rahmen des gemeinsamen Hochschulsonderprogramms III von Bund und Ländern) and performed in the framework of the BIOMED project BMHA-CT97-2485.

- [6] B. Lippert, M. Leng in *Topics in Biological Inorganic Chemistry, Vol. 1 (Metallopharmaceuticals 1)* (Eds.: M. J. Clarke, P. J. Sadler), Springer, Berlin, **1999**, pp. 117–142, and references therein.
- [7] R. Manchanda, S. U. Dunham, S. J. Lippard, *J. Am. Chem. Soc.* **1996**, *118*, 5144–5145.
- [8] J. Schliepe, U. Berghoff, B. Lippert, D. Cech, *Angew. Chem.* **1996**, *108*, 705–707; *Angew. Chem. Int. Ed. Engl.* **1996**, *35*, 646–648.
- [9] Removal of the 1-*N*-cyclohexylmethylthymine ligand is more efficient than reported for 1-*N*-methylthymine: U. Berghoff, K. Schmidt, M. Janik, G. Schröder, B. Lippert, *Inorg. Chim. Acta* **1998**, *269*, 135–142.
- [10] S. B. Rajur, J. Robles, K. Wiederholt, R. G. Kuimelis, L. W. McLaughlin, *J. Org. Chem.* **1997**, *62*, 523–529.
- [11] Recently the synthesis of a thymine-tethered Pt^{IV} complex has been reported: S. Ren, L. Cai, B. M. Segal, *J. Chem. Soc. Dalton Trans.* **1999**, 1413–1422. The authors present, however, no evidence sustaining the compatibility of this complex with automated DNA synthesis.
- [12] J. A. Zoltewicz, D. F. Clark, T. W. Sharpless, G. Grahe, *J. Am. Chem. Soc.* **1970**, *92*, 1741–1750.
- [13] D. T. Browne, J. Eisinger, N. J. Leonard, *J. Am. Chem. Soc.* **1968**, *90*, 7302–7323.
- [14] C. J. L. Lock, P. Pilon, B. Lippert, *Acta Crystallogr. Sect. B* **1979**, *35*, 2533–2537.
- [15] O. Krizanovic, M. Sabat, R. Beyerle-Pfntür, B. Lippert, *J. Am. Chem. Soc.* **1993**, *115*, 5538–5548.
- [16] M. J. Gait in *An Introduction to Modern Methods of DNA Synthesis* (Ed.: M. J. Gait), IRL, Oxford, **1984**, pp. 1–22.



Scheme 1. Retrosynthetic analysis. Ar = 2,6-dimethylphenyl.

Total Synthesis of the Antimicrotubule Agent (+)-Discodermolide Using Boron-Mediated Aldol Reactions of Chiral Ketones**

Ian Paterson,* Gordon J. Florence, Kai Gerlach, and Jeremy P. Scott

Discodermolide (**1**) is a unique polyketide isolated in 1990 by Gunasekera et al. at the Harbor Branch Oceanographic Institute, Florida, from the Caribbean sponge *Discodermia dissoluta*.^[1] Structurally (Scheme 1), it bears 13 stereogenic centers, a tetrasubstituted δ -lactone (C₁-C₅), one di- and one tri-substituted *Z*-alkene, a carbamate moiety, and a terminal *Z*-diene. Discodermolide displays potent activity as an anti-mitotic agent, with a similar mechanism of action to taxol (paclitaxel), namely by stabilizing microtubules and promoting the polymerization of tubulin.^[2] It inhibits the growth of human breast cancer cells in vitro, as well as paclitaxel-resistant ovarian and colon cancer cells, and other multidrug

resistant cells.^[3] Hence, discodermolide is a particularly promising candidate for development in cancer chemotherapy, but its use is severely limited by its scarce supply (0.002 % w/w isolation yield)^[1] from the rare sponge source.

To date, two total syntheses of the natural (+)-discodermolide and three syntheses of the antipodal (–)-discodermolide have been reported,^[4] together with various synthetic approaches.^[5] Schreiber and co-workers^[4a] have synthesized both antipodes and established the absolute configuration, as well as preparing a number of structural analogues.^[4b] Despite these impressive efforts, there is still a pressing demand for developing a more practical and efficient synthetic route to (+)-discodermolide.

Herein, we describe a highly convergent total synthesis, which has the potential to provide useful quantities of (+)-discodermolide. Notably, our route is entirely different from earlier syntheses and is based on a novel aldol-coupling strategy, which also employs aldol reactions of chiral ketones to construct the three key subunits **2**, **3**, and **4** (Scheme 1). Our retrosynthetic analysis is based on a C₆-C₇ disconnection which leads back to the (C₁-C₆) methyl ketone **2** and the enal **5**. Further disassembly of **5** gives the (C₉-C₁₆) ester **3** and the (C₁₇-C₂₄) aldehyde **4**.

As shown in Scheme 2 the synthesis of the C₁-C₆ subunit **2** began with a boron-mediated *anti*-selective aldol reaction between the readily available^[6] ethyl ketone (*S*)-**6** and acetaldehyde. The intermediate aldolate was reduced in situ with LiBH₄ to give diol **7** (98 %, >97 % diastereoselectivity (ds)).^[6a] Protection as the bis-*tert*-butyldimethylsilyl (TBS) ether **8**, followed by methanolysis using catalytic CSA in MeOH/CH₂Cl₂ at 0 °C, gave C₅-alcohol **9** in 70 % yield, together with starting material and diol **7**, which were recycled accordingly. After debenzoylation, diol **10** was converted into subunit **2** by sequential double Swern oxidation, NaClO₂ oxidation, and esterification. This three-step operation was carried out without chromatography in 93 % yield. The

[*] Dr. I. Paterson, G. J. Florence, Dr. K. Gerlach, Dr. J. P. Scott
University Chemical Laboratory
Lensfield Road, Cambridge CB2 1EW (UK)
Fax: (+44) 1223-336-362
E-mail: ip100@cus.cam.ac.uk

[**] We thank the EPSRC (Grants GR/M46686 and L41646, and studentships for G.J.F. and J.P.S.), the DFG (postdoctoral fellowship for K.G.), Merck, and Novartis for support, and Dr. S. P. Gunasekera (Harbor Branch Oceanographic Institute) for kindly providing a sample of natural (+)-discodermolide. We also thank Prof. A. B. Holmes (Cambridge) for helpful discussions regarding the Claisen rearrangement chemistry and Dr. P. A. Wallace for contributions to early studies.